The evolving role of natural products in drug discovery

Nature Reviews Drug Discovery

Volumn 4, Issue 3, 2005, Pages 206-220

  Koehn, Frank E ^a   Carter, Guy T ^a  

^a WYETH RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,3 BETA GLUCAN SYNTHASE; ARTEMISININ; AZEPINE DERIVATIVE; BRYOSTATIN 1; BRYOSTATIN 2; CALICHEAMICIN; COLCHICINE; COMBRETASTATIN; CRYPTOPHYCIN DERIVATIVE; CYCLODEPSIPEPTIDE; DISCODERMOLIDE; EPOTHILONE A; FK 506 BINDING PROTEIN; HEMIN; HUN 7293; IMMUNOPHILIN; MANNOPEPTIMYCIN; MEVINOLIN; MICAFUNGIN; NATURAL PRODUCT; NEUROTRANSMITTER; PACLITAXEL; PIMECROLIMUS; PODOPHYLLOTOXIN; POLYPEPTIDE ANTIBIOTIC AGENT; RAPAMYCIN; RESERPINE; TACROLIMUS; TUBULIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

AFFINITY CHROMATOGRAPHY; ANTIBACTERIAL ACTIVITY; ANTINEOPLASTIC ACTIVITY; ATOPIC DERMATITIS; BIOCOMPATIBILITY; CELL FREE SYSTEM; COLCHICUM; DRUG DETERMINATION; DRUG INDUSTRY; DRUG MECHANISM; DRUG RESEARCH; DRUG STRUCTURE; DRUG TARGETING; ELECTROSPRAY MASS SPECTROMETRY; EXPECTATION; FINANCIAL MANAGEMENT; GRAFT REJECTION; GRAM NEGATIVE BACTERIUM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIGH THROUGHPUT SCREENING; HUMAN; ION CYCLOTRON RESONANCE MASS SPECTROMETRY; KIDNEY TRANSPLANTATION; LIQUID CHROMATOGRAPHY; LIVER TRANSPLANTATION; MASS SPECTROMETRY; MINIMUM INHIBITORY CONCENTRATION; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; NUCLEAR OVERHAUSER EFFECT; PATENT; PHARMACOPHORE; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; REVIEW; STAPHYLOCOCCUS AUREUS; STRUCTURE ACTIVITY RELATION; TAXUS BREVIFOLIA; TECHNOLOGY;

BIOLOGICAL PRODUCTS; DRUG DESIGN; HUMANS; PATENTS; STRUCTURE-ACTIVITY RELATIONSHIP; TECHNOLOGY, PHARMACEUTICAL;

EID: 14944383798     PISSN: 14741776     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrd1657     Document Type: Review

References (111)

1. Newman, D. J., Cragg, G. M. & Snader, K. M. Natural products as a source of new drugs over the period 1981-2002. J. Nat. Prod. 66, 1002-1037 (2003).
2. Projan, S. J. Infectious diseases in the 21st century: increasing threats, fewer new treatments and a premium on prevention. Cur. Opin. Pharmacol. 3, 457-458 (2003).
3. Kirsop, B. E. The convention on biological diversity: some implications for microbiology and microbial collections. J. Indust. Microbiol. Biotech. 17, 505-511 (1996).
4. Projan S. J. Why is big pharma getting out of antibacterial drug discovery? Cur. Opin. Microbiol. 6, 427-30 (2003).
5. Ajay, W. P. W. & Murcko, M. Can we learn to distinguish between 'Drug-Like' and 'Nondrug-like' molecules? J. Med. Chem. 41, 3314-3324 (1998).
6. Sadowski, J. & Kubinyi, H. Scoring scheme for discriminating between drugs and nondrugs. J. Med. Chem. 41, 3325-3329 (1998).
7. Newman, D., Cragg, G., Kingston, D. in The Practice of Medicinal Chemistry (ed. Wermuth, C. G.) 91-109 (Academic, London, 2003).
8. Feher, M. & Schmidt, J. M. Property distributions: Differences between drugs, natural products, and molecules from combinatorial chemistry. J. Chem. Inf. Comput. Sci. 43, 218-227 (2003).
9. Lipinski, C. A., Lombardo, F., Dominy, B. W. & Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development setlings. Adv. Drug Del. Rev. 23, 3-25 (1997).
10. Lee, M. L. & Schneider, G. Scaffold architecture and pharmacophoric properties of natural products and trade drugs: Application in the design of natural product-based combinatorial libraries J. Comb. Chem. 3, 284-289 (2001).
11. Stahura, F., Godden, J. W., Ling, X. & Bajorath, J. Distinguishing between natural products and synthetic molecules by descriptor Shannon entropy analysis and binary QSAR calculations. J. Chem. Inf. Comput. Sci. 40, 1245-1252 (2000).
12. Henkel, T., Brunne, R., Muller, H. & Reichel, F. Statistical investigation of structural complementarity of natural products and synthetic compounds. Angew. Chem. Int. Ed. Engl. 38, 643-647 (1999).
13. Martin, Y. C. Diverse viewpoints on computational aspects of molecular diversity. J. Comb. Chem. 3, 231-250 (2001).
14. Martin, Y. C. & Critchlow, R. E. Beyond mere diversity: tailoring combinatorial libraries for drug discovery. J. Comb. Chem. 1, 32-45 (1999).
15. Evans, B. E. et al. Methods for drug discovery: development of potent, selective, orally effective cholecystokinin antagonists. J. Med. Chem. 31, 2235-2246 (1988).
16. Chothia, C. One thousand families for the molecular biologist. Nature 357, 543-544 (1992).
17. Zhang, C. & DeLisi, C. Estimating the number of protein folds. J. Mol. Biol. 284, 1301-1305 (1998).
18. Salem, G. M., Hutchinson, E. G., Orengo, C. A. & Thornton, J. M. Correlation of observed fold frequency with the occurrence of local structural motifs. J. Mol. Biol. 287, 969-981 (1999).
19. Holm, L. & Sander, C. Mapping the protein universe. Science 273, 595-603 (1996).
20. Hou, J., Sims, G., Zhang, C. & Kim, S-H. A global representation of the protein fold space. Proc. Natl Acad. Sci. USA 100, 2386-2390 (2003).
21. Anantharaman, V., Aravind, L. & Koonin, E. V. Emergence of diverse biochemical activities in evolutionarily conserved structural scaffolds of proteins. Cur. Opin. Chem. Biol. 7, 12-20 (2003).
22. Breinbauer, R., Vetter, I. R. & Waldmann, H. From protein domains to drug candidates- Natural products as guiding principles in the design and synthesis of compound libraries. Angew. Chem. Int. Ed. 41, 2878-2890 (2002).
23. Atuegbu, A., MacLean, D., Nguyen, C., Gordon, E. M. & Jacobs, J. W. Combinatorial modification of natural products: Preparation of un-encoded and encoded libraries of Rauwolfia alkaloids. Bioorg. Med. Chem. 4, 1097-1106 (1996).
24. Xaio, X. Y., Parandoosh, Z. & Nova, M. P. Design and synthesis of a taxoid library using radiofrequency encoded combinatorial chemistry. J. Org. Chem. 62, 6029-6033 (1997).
25. Xu, R., Grieveldinger, G., Marenus, L. E., Cooper, A. & Ellman, J. A. Combinatorial library approach for the identification of synthetic receptors targeting vancomycin-resistant bacteria. J. Am. Chem. Soc. 121, 4898-4899 (1999).
26. Nicolaou, K. C., Winssinger, N. Hughes, R., Smethurst, C. & Cho, S. Y. New selenium-based safety-catch linkers: solid-phase semisynthesis of vancomycin. Angew. Chem. Int. Ed. 39, 1084-1088 (2000).
27. Nicolaou, K. C., Pfefferkorn, J. A., Roecker, A. J., Cao, G.-Q. & Barluenga, S. Natural product-like combinatorial libraries based on privileged structures 1. General principles and solid phase synthesis of benzopyrans. J. Am. Chem. Soc. 122, 9939-9953 (2000).
28. Nicolaou, K. C. et al. Natural product-like combinatorial libraries based on privileged structures. 2. Construction of a 10,000-membered benzopyran library by directed split-and-pool chemistry using NanoKans and optical encoding. J. Am. Chem. Soc. 122, 9954-9967 (2000).
29. Kissau, L., Stahl, P., Mazitschek, R., Giannis, A. & Waldmann, H. Development of natural product-derived receptor tyrosine kinase inhibitors based on conservation of protein domain fold. J. Med. Chem. 46, 2917-2931 (2003).
30. Peczuh, M. W. & Hamilton, A. D. Peptide and protein recognition by designed molecules. Chem. Rev. 100, 2479-2494 (2000).
31. Dumont, F. J. FK506, An immunosuppressant targeting calcineurin function. Curr. Med. Chem. 7, 731-748 (2000).
32. Abraham, R. T. & Wiederrecht, G. J. Immunophamacology of rapamycin. Ann. Rev. Immunol. 14, 483-510 (1996).
33. Hersperger, R. & Keller, T. H. Ascomycin derivatives and their use as immunosuppressive agents. Drugs Future 25, 269-277 (2000).
34. Takahashi, N. in Macrolide Antibiotics 2nd Edn (ed. Omura, S.) 577-621 (Academic, London, 2002).
35. Pong, K. & Zaleska, M. M. Therapeutic implications for immunophilin ligands in the treament of neurodegenerative diseases. Curr. Drug Targets CNS Neurol. Disord. 2, 61-72 (2003).
36. Jordan, M. A. Mechanism of action of antitumor drugs that interact with microtubules and tubulin. Curr. Med. Chem. 2, 1-17 (2002).
37. Kowalski, R. J. et al. The microtubule-stabilizing agent discodermolide competitively inhibits the binding of paclitaxel (Taxol) to tubulin polymers, enhances tubulin nucleation reactions more potently than paclitaxel, and inhibits the growth of paclitaxel-resistant cells. Mol. Pharmacol. 52, 613-622 (1997).
38. Bai, R., Cichacz, Z. A., Herald, C. L., Pettit, G. R. & Hamel, E. Spongistatin 1, a highly cytotoxic, sponge-derived, marine natural product that inhibits mitosis, microtubule assembly, and the binding of vinblastine to tubulin. Mol. Pharmacol. 44, 757-66 (1993).
39. Loganzo, F. et al. HTI-286, a synthetic analogue of the tripeptide hemiasterlin, is a potent antimicrotubule agent that circumvents P-glycoprotein-mediated resistance in vitro and in vivo. Cancer Res. 63, 1838-1845 (2003).
40. Sackett, D. L. Podophyllotoxin, steganacin and combretastatin: natural products that bind at the colchicine site of tubulin. Pharmacol. Therap. 59, 163-228 (1993).
41. Silverman, L., Campbell, R. & Broach, J. R. New assay technologies for high throughput screening. Curr. Opin. Chem. Biol. 2, 397-403 (1998).
42. Cohen, P. Protein kinases- The major drug targets of the 21st century? Nature Rev. Drug Discov. 1, 309-316 (2002).
43. Zaman, G. J. R., Garritsen, A., de Boer, T. & van Boeckel, C. A. Fluorescence assays for high throughput screening of protein kinases. Comb. Chem. High Throughput Screen. 6, 313-320 (2003).
44. Fowler, A. et al. An evaluation of fluorescence polarization and lifetime discriminated polarization for high throughput screening of serine/threonine kinases. Anal. Biochem. 308, 223-231 (2002).
45. Turek-Etienne, T. C. et al. Evaluation of fluorescent compound interference in 4 fluoroescence polarization assays: 2 kinases, 1 protease, and 1 phosphatase. J. Biomol. Screen. 8, 176-184 (2003).
46. Eldridge, G. R. et al. High-throughput method for the production and analysis of large natural product libraries for drug discovery. Anal. Chem. 74, 3963-3971 (2002).
47. Abel, U., Koch, C., Speitling, M. & Hansske, F. G. Modern methods to produce natural-product libraries. Curr. Opin. Chem. Biol. 6, 453-458 (2002).
48. Cummins, L. L. et al. Multitarget affinity/specificity screening of natural products:Finding and characterizing high affinity ligands from complex mixtures by using high performance mass spectrometry. J. Nat. Prod. 66, 1186-1190 (2003).
49. Firn, R. D. & Jones, C. D. Natural products - a simple model to explain chemical diversity. Nat. Prod. Rep. 20, 382-391 (2003).
50. Chabala, J. C. et al. Ivermectin, a new broad-spectrum antiparasitic agent. J. Med. Chem. 23, 1134-1136 (1980).
51. He, H. et al. Mannopeptimycins, novel antibacterial glycopeptides from Streptomyces hygroscopicus, LL-AC98. J. Am. Chem. Soc. 124, 9729-9736 (2002).
52. De Voe, S. E. & Kunstmann, M. P. Antibiotic AC98 and production. US Patent 3,495,004 (1970).
53. Ruzin, A. et al. Mechanism of action of the mannopeptimycins, a novel class of glycopeptide antibiotics active against vancomycin-resistant Gram-positive bacteria. Antimicrob. Agent. Chemother. 48, 728-738 (2004).
54. He, H. et al. Mannopeptimycin esters and carbonates, potent antibiotic agents against drug resistant bacteria. Bioorg. Med. Chem. Lett. 14, 279-282 (2004).
55. Sum, P. E., et al. Synthesis and evaluation of ether and halogenated derivatives of mannopeptimycin glycopeptide antibiotic. Biorg. Med. Chem. Lett. 13, 2805-2808 (2003).
56. Dushin, R. G. et al. Hydrophobic acetal and ketal derivatives of mannopeptimycin-α and AC98-0053: semisynthetic glycopeptides with potent activity against Gram-positive bacteria. J. Med. Chem. 47, 3487-3490 (2004).
57. Strege, M. A. High-performance liquid chromatographic-electrospray ionization mass spectrometric analyses for the integration of natural products with modern high-throughput screening. J. Chrom. B 725, 67-68 (1999).
58. Nielsen, K. F. & Smedsgaard, J. Fungal metabolite screening: database of 474 mycotoxins and fungal metabolites for dereplication by standardised liquid chromatography-UV-mass spectrometry methodology. J. Chrom. A 1002, 111-136 (2003).
59. Freeman, R. & Morris, G. A. Two-dimensional Fourier transformation in NMR. Bull. Magn. Res. 1, 1-26 (1979).
60. Bax, A., Aszalos, A., Dinya, Z. & Sudo, K. Structure elucidation of the antibiotic desertomycin through the use of new two-dimensional NMR techniques. J. Am. Chem. Soc. 108, 8056-8063 (1986).
61. Schwalbe, H. & Kessler, H. 900 MHz NMR spectrometer in Munich and Frankfurt. Nachrichten aus der Chemie 51, 412-417 (2003).
62. Sandvoss, M., Preiss, A., Levsen, K., Weisemann, R. & Spraul, M. Two new asterosaponins from the starfish Asteries rubens: application of a cryogenic NMR probe head. Magn. Res. Chem. 41 949-954 (2003).
63. Olson, D. L. et al. Microflow NMR: concepts and capabilities. Anal. Chem. 76, 2966-2974 (2002).
64. Serber, Z. et al. New carbon-detected protein NMR experiments using cryoProbes. J. Am. Chem. Soc. 122, 3554-3555 (2000).
65. 13C NMR assignments and the three-dimensional PFG NOESY-HMQC spectrum. J. Am. Chem. Soc. 117, 7019-7020 (1995).
66. He, H. et al. Lomaiviticins A and B, potent antitumor antibiotics from Micromonospora Lomaivitiensis. J. Am. Chem. Soc. 123, 5352-5363 (2001).
67. n, the Top-Down/Bottom-Up approach, and HPLC ESI capillary-skimmer CID FTMS. Anal. Chem. 75, 2730-2739 (2003).
68. Gunasekera, A. P., Gunaskera, M., Longley, R. E. & Schulte, G. K. Discodermolide: a new bioactive polyhydroxylated lactone from the marine sponge Discodermia dissoluta. J. Org. Chem. 65, 4912-4915 (1990).
69. Towle, M. J. et al. In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin B. Cancer Res. 61, 1013-1021 (2001).
70. Kuznetsov, G. et al. Induction of morphological and biochemical apoptosis following prolonged mitotic blockage by halichondrin B macrocyclic ketone analog E7389. Cancer Res. 64 5760-5766 (2004).
71. Schenk, T. et al. A Generic assay for phosphate-consuming or -releasing enzymes coupled on-line to liquid chromatography for lead finding in natural products. Anal. Biochem. 316, 118-126 (2003).
72. Cummins, L. L. et al. Multitarget affinity/specificity screening of natural products finding and characterizing high-affinity ligands from complex mixtures by using high-performance mass spectrometry. J. Nat. Prod. 66, 1186-1190 (2003).
73. Schriemer, D. C., Bundle, D. R., Li, L. & Hindagaul, O. Microscale frontal affinity chromatography with mass spectrometric detection: a new method for the screening of compound libraries. Angew. Chem. Int. Ed. 37, 3383-3387 (1998).
74. Chan, N. W. C., Lewis, D. F., Rosner, P. J., Kelly, M. A. & Schriemer, D. C. Frontal affinity chromatography-mass spectrometry assay technology for multiple stages of drug discovery: applications of a chromatographic biosensor. Anal. Biochem. 319, 1-12 (2003).
75. Zhu, L., Chen, L., Luo, H. & Xu, X. Frontal affinity chromatography combined on-line with mass spectometry: a tool for the binding study of different epidermal growth factor receptor inhibitors. Anal. Chem. 75, 6388-6393 (2003).
76. Wolfender, J-L., Ndjoko, K. & Hostettmann, K. Liquid chromatography with ultraviolet absorbance-mass spectrometric detection and with nuclear magnetic resonance spectroscopy: a powerful combination for the on-line structural investigation of plant metabolites. J. Chrom. A 1000, 437-455 (2003).
77. Exarchou, V., Godejohann, M., van Beek, T. S., Gerothanassis, I. P. & Vervoort, J. LC-UV-solid-phase extraction-NMR-MS combined with a cryogenic flow probe and its application to the identification of compounds present in greek oregano. Anal. Chem. 75, 6288-6294 (2003).
78. Laude, D. A. &, Wilkins, C. L. Direct-linked analytical scale high-performance liquid chromatography/nuclear magnetic resonance spectrometry. Anal. Chem. 56, 2471-2475 (1984).
79. Albert, K. Liquid chromatography-nuclear magnetic resonance spectroscopy. J. Chrom. 856, 199-211 (1999).
80. Wolfender, J.-L., Ndjoko, K. & Hostettmann, K. The potential of LC-NMR in phytochemical analysis. Phytochem. Anal. 12, 2-22 (2001).
81. Schaller, F., Wolfender, J.-L., Hostettmann, K. & Mavi, S. New antifungal 'quinone methide' diterpenes from Bobgunnia madagascariensis and study of their interconversion by LC/NMR Helv. Chim. Act. 84, 222-229 (2001).
82. Lommen, A., Godejohann, M., Venema, D. P., Hollman, P. C. H., Spraul, M. Application of directly coupled HPLC-NMR-MS to the identification and confirmation of quercetin glycosides and phloretin glycosides in apple peel. Anal. Chem. 72, 1793-1797 (2000).
83. Spraul, M. et al. Advancing sensitivity for LC-NMR-MS using a cryoflow probe: application to analysis of acetominophen metabolites in urine. Anal. Chem. 75, 1546-1551 (2003).
84. Wu, N., Webb, A., Peck, T. L., Sweedler, J. V. Online NMR detection of amino acids and peptides in microbore LC. Anal. Chem. 67, 3101-3107 (1995).
85. Khosla, C. & Keasling, J. D. Metabolic engineering for drug discovery and development. Nature Rev. Drug Discov. 2, 1019-1025 (2003).
86. Nicolaou, K. C. et al. Total synthesis of apoptolidin: construction of enantiomerically pure fragments. J. Am. Chem. Soc. 125, 15433-15442 (2003).
87. Lin, S. et al. Total syntheses of TMC-95A and B via a new reaction leading to Z-enamides. Some preliminary findings as to SAR. J. Am. Chem. Soc. 126, 6347-6355 (2004).
88. Wender, P. A. et al. Modeling of the bryostatins to the phorbol ester pharmacophore on protein knase C. Proc. Natl Acad. Sci. USA 85, 7197-201 (1988).
89. Wender, P. A. et al. The design, computer modeling, solution structure, and biological evaluation of synthetic analogs of bryostatin 1. Proc. Natl Acad. Sci. USA 95, 6624-6629 (1998).
90. Wender, P. A., DeBrabander, P. G, Hinkle, K. W., Lippa, B., Pettit, G. R. Synthesis and biological evaluation of fully synthetic bryostatin analogues. Tet. Lett. 39, 8625-8628 (1998).
91. Wender, P. A. et al. The practical synthesis of a novel and highly potent analogue of bryostatin. J. Am. Chem. Soc. 124 13648-13649 (2002).
92. Hommel, U., Weber, H-P., Oberer, L., Naegeli, H. U., Oberhauser, B. & Foster, C. A. The 3D-structure of a natural inhibitor of cell adhesion molecule expression. FEBS Lett. 379, 69-73 (1996).
93. Chen, Y., Bilban, M., Foster, C. A. & Boger, D. L. Solution-phase parallel synthesis of a pharmacophore library of HUN-7293 analogues: A general chemical mutagenesis approach to defining structure-function properdes of naturally occurring cyclic (depsi)peptides. J. Am. Chem. Soc. 124, 5431-5440 (2002).
94. Smith, III, A. B., Cho, Y. S., Pettit, G. R. & Hirschmann, R. Design, synthesis, and evaluaton of azepine-based cryptophycin mimetics. Tetrahedron 59, 6991-7009 (2003).
95. Lee, M. D., Durr, F. E., Hinman, L. M., Hanmann, P. R. & Ellestad, G. A. The calicheamicins. Adv. Med. Chem. 2, 31-66 (1993).
96. Damle, N. K. & Frost, P. Antibody-targeted chemotherapy with immunoconjugates of calicheamicin. Curr. Opin. Pharm. 3, 386-390 (2003).
97. Hamann, P. R. et al. Gemtuzumab ozogamicin, A potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Bioconj. Chem. 13, 47-58 (2002).
98. Burke, M. D. & Schreiber, S. L. A planning strategy for diversity oriented synthesis. Angew. Chem. Int. Ed. 43, 46-58 (2004).
99. Koehler, A. N., Shamji, A. F. & Schreiber, S. L. Discovery of an inhibitor of a transcription factor using small molecule microarrays and diversity-oriented synthesis. J. Am. Chem. Soc. 125, 8420-8421 (2003).
100. Brik, A. M. et al. Rapid diversity-oriented synthesis in microtiter plates for in situ screening of HIV protease inhibitors. Chembiochem 4, 1246-1248 (2003).
101. Niggemann, J., Michaelis, K., Frank, R., Zander, N. & Höfle, G. Natural product-derived building blocks for combinatorial synthesis. Part 1. Fragmentation of natural products from myxobacteria. J. Chem. Soc. Perkin. Trans. 1, 2490-2503 (2002).
102. ter Haar, E. et al. Discodermolide, A cytotoxic agent that stabilizes microtubules more potently than taxol. Biochemistry 35, 243-250 (1996).
103. Nerenberg, J. B., Hung, D. T., Somers, P. K., Schreiber, S. L. Total synthesis of the immunosuppressive agent (-)-discodermolide. J. Am. Chem. Soc. 115, 12621-12622 (1993).
104. Smith, A. B. et al. Evolution of a gram-scale synthesis of (+)-discodermolide. J. Am. Chem. Soc. 122, 8654-8664 (2000).
105. Paterson, I., Florence, G. J., Gerlach, K. & Scott, J. P. Total synthesis of the antimicrotubule agent (+) disodermolide using boron-mediated aldol reactions of chiral ketones. Angew. Chem. Int. Ed. 39, 377 (2000).
106. Marshall, J. A. & Johns, B. A. Total synthesis of (+)-discodermolide. J. Org. Chem. 63, 7885-7892 (1998).
107. Mickel, S. J. et al. Large scale synthesis of the anti-cancer marine natural product (+)-discodermolide. Part 1. Org. Proc. Res. Dev. 8, 92-100 (2004).
108. Mickel, S. J. et al. Large scale synthesis of the anti-cancer marine natural product (+)-discodermolide. Part 2. Org. Proc. Res. Dev. 8, 101-106 (2004).
109. Mickel, S. J. et al. Large scale synthesis of the anti-cancer marine natural product (+)-discodermolide. Part 3. Org. Proc. Res. Dev. 8, 107-112 (2004).
110. Mickel, S. J. et al. Large scale synthesis of the anti-cancer marine natural product (+)-discodermolide. Part 4. Org. Proc. Res. Dev. 8, 113-121 (2004).
111. Mickel, S. J. et al. Large scale synthesis of the anti-cancer marine natural product (+)-discodermolide. Part 5. Org. Proc. Res. Dev. 8, 122-130 (2004).